Source: European Medicines Agency (EU) Revision Year: 2022 Publisher: Helsinn Birex Pharmaceuticals Ltd., Damastown, Mulhuddart, Dublin 15, Ireland
Ledaga is indicated for the topical treatment of mycosis fungoides-type cutaneous T-cell lymphoma (MF-type CTCL) in adult patients (see section 5.1).
Treatment with Ledaga should be initiated by an appropriately experienced physician.
A thin film of Ledaga should be applied once daily to affected areas of the skin.
Treatment with Ledaga should be stopped for any grade of skin ulceration or blistering, or moderately severe or severe dermatitis (e.g., marked skin redness with oedema). Upon improvement, treatment with Ledaga can be restarted at a reduced frequency of once every 3 days. If reintroduction of treatment is tolerated for at least 1 week, the frequency of application can be increased to every other day for at least 1 week and then to once-daily application if tolerated.
The dosing recommendation for elderly patients (≥65 years old) is the same as for younger adult patients (see section 4.8).
The safety and efficacy of Ledaga in children aged 0 to 18 years have not been established. No data are available.
Ledaga is for topical application to the skin.
The following instructions should be followed by patients or caregivers when applying Ledaga:
No cases of overdose after cutaneous use of Ledaga were reported during the clinical development programme or post-marketing period. Management of overdose should consist of washing the exposed area with water.
Frozen tube: 4 years in the freezer (–15°C to –25°C).
After defrosting: 60 days in the refrigerator (+2°C to +8°C).
Ledaga should be removed from the refrigerator just prior to application and returned to the refrigerator immediately after each use in its box inside the child-resistant, transparent, sealable, plastic bag.
Unopened tube: Store and transport frozen (−15°C to −25°C) or refrigerated (+2°C to +8°C).
After defrosting: Store and transport refrigerated (+2°C to +8°C).
Ledaga is provided in a white aluminium tube with an inner lacquer and an aluminium seal and a white polypropylene screw cap. Each tube contains 60 g of gel.
Ledaga is a cytotoxic medicinal product.
Caregivers must wear nitrile gloves when handling Ledaga. Patients and caregivers must wash hands after handling Ledaga.
Ledaga is an alcohol-based product and is flammable. The recommended application instructions should be followed (see section 4.2).
Unused refrigerated Ledaga should be discarded after 60 days, together with the plastic bag.
Any unused medicinal product or waste material, including the plastic bag and the nitrile gloves used for application, must be disposed of in accordance with local requirements.
© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.